Methods of treating conditions using anti-IL-6 antibodies

1. A method for suppressing rheumatoid arthritis in an animal, comprising:

administering a composition comprising an effective amount of an IL-6 antibody to said animal, wherein the IL-6 antibody comprises a light chain variable region amino acid sequence of SEQ ID NO:97 and a heavy chain variable region amino acid sequence of SEQ ID NO:99.

2. The method according to claim 1 , wherein said effective amount is about 0.001-50 mg/kilogram of said animal.

3. The method according to claim 1 , wherein said administering is by subcutaneous method.

4. The method according to 1 , further comprising administering, prior, concurrently or after said administering, at least one composition comprising an effective amount of a cytokine antagonist.

5. A method for suppressing rheumatoid arthritis in an animal, comprising:

administering a composition comprising an effective amount of an IL-6 antibody to said animal, wherein the IL-6 antibody comprises a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:3, a CDRL2 amino acid sequence of SEQ ID NO:21, a CDRL3 amino acid sequence of SEQ ID NO:29, a complementarity determining region heavy chain 1 (CDRH1) amino acid sequence of SEQ ID NO:39, a CDRH2 amino acid sequence of SEQ ID NO:59, and a CDRH3 amino acid sequence of SEQ ID NO:89.

6. The method according to claim 5 , wherein said effective amount is about 0.001-50 mg/kilogram of said animal.

7. The method according to claim 5 , wherein said administering is by subcutaneous method.

8. The method according to 5 , further comprising administering, prior, concurrently or after said administering, at least one composition comprising an effective amount of a cytokine antagonist.

9. A method for suppressing rheumatoid arthritis in an animal, comprising:

administering a composition comprising an effective amount of an IL-6 antibody to said animal, wherein the IL-6 antibody comprises at least one light chain variable region and one heavy chain variable region, said light chain variable region comprising:

a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:132 comprising the sequence S-X 1 -X 2 -X 3 -X 4 -V-X 5 -Y-M-Y, wherein X 1 is A or G, X 2 is S or R, X 3 is H, I, S, or Y, X 4 is S or Y, and X 5 is S or F;

a CDRL2 amino acid sequence of SEQ ID NO:133 comprising the sequence D-X 6 -S-X 7 -L-X 8 -S, wherein X 6 is F, L, M, or T, X 7 is N or E, and X 8 is A or T; and

a CDRL3 amino acid sequence of SEQ ID NO:134 comprising the sequence X 9 -X 10 -W-S-G-Y-P-Y-T, wherein X 9 is M, C, or S, and X 10 is Q or C;

said heavy chain variable region comprising:

a complementarity determining region heavy chain 1 (CDRH1) amino acid sequence of SEQ ID NO:135 comprising the sequence G-F-X 11 -X 12 -S-X 13 -F-A-X 14 -S, wherein X 11 is T or Q, X 12 is F, S, or T, X 13 is S or P, and X 14 is L or M;

a CDRH2 amino acid sequence of SEQ ID NO:136 comprising the sequence K-X 15 -S-X 16 -G-G-S-X 17 -X 18 -Y-X 19 -X 20 -D-T-X 21 -X 22 -X 23 , wherein X 15 is A or I, X 16 is S or P, X 17 is Y or W, X 18 is T, E, or Y, X 19 is Y or F, X 20 is P, S, D, or F, X 21 is V or D, X 22 is T or A, and X 23 is G or P; and

a CDRH3 amino acid sequence of SEQ ID NO:137 comprising the sequence Q-L-W-G-X 24 -Y-A-L-D-X 25 , wherein X 24 is S, Y, T, or N, and X 25 is Y, T, F, or I.

10. The method according to claim 9 , wherein said effective amount is about 0.001-50 mg/kilogram of said animal.

11. The method according to claim 9 , wherein said administering is by subcutaneous method.

12. The method according to 9 , further comprising administering, prior, concurrently or after said administering, at least one composition comprising an effective amount of a cytokine antagonist.